Virtus ETF Advisers LLC Aldeyra Therapeutics, Inc. Transaction History

Virtus ETF Advisers LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 07, 2023	SELL	$6.11 - $8.16 $5,749 - $7,678	-941 Reduced 9.05%	9,460 $63,000
Q2 2023 Aug 14, 2023	BUY	$7.11 - $11.89 $73,951 - $123,667	10,401 New	10,401 $87,000
Q2 2022 Aug 12, 2022	SELL	$2.43 - $4.85 $55,756 - $111,283	-22,945 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$3.25 - $5.17 $4,397 - $6,995	-1,353 Reduced 5.57%	22,945 $102,000
Q4 2021 Feb 14, 2022	BUY	$3.5 - $9.63 $24,507 - $67,429	7,002 Added 40.48%	24,298 $97,000
Q3 2021 Nov 15, 2021	SELL	$7.94 - $11.31 $7,185 - $10,235	-905 Reduced 4.97%	17,296 $152,000
Q2 2021 Aug 10, 2021	BUY	$10.44 - $14.85 $190,018 - $270,284	18,201 New	18,201 $206,000

117

36.4M

196K

142K

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $279M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Virtus ETF Advisers LLC with notifications on news.